{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "November 2019, 37-year-old woman diagnosed with left lung adenocarcinoma with hilar mediastinal lymph node, left supraspinal lymph node, and extensive bone metastases (cT4N3M1c, stage IVB). Baseline chest CT scan and head MRI at diagnosis in November 2019.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Lung cancer, unspecified",
              "status": "active",
              "onset_date": "2019-11"
            },
            {
              "code": "C77.9",
              "label": "Secondary and unspecified malignant neoplasm of lymph node, unspecified",
              "status": "active",
              "onset_date": "2019-11"
            },
            {
              "code": "C79.51",
              "label": "Secondary malignant neoplasm of bone",
              "status": "active",
              "onset_date": "2019-11"
            }
          ],
          "imaging": [
            {
              "type": "Chest CT scan",
              "body_part": "Lung",
              "modality": "CT",
              "date": "2019-11"
            },
            {
              "type": "Head MRI",
              "body_part": "Head",
              "modality": "MRI",
              "date": "2019-11"
            }
          ]
        }
      },
      "custom_id": "graph_076_N0"
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Tumor tissue NGS revealed EGFR exon 18 p.G719S mutation and EGFR exon 20 p.S768I mutation. NGS revealed the retention of EGFR exon 18 p.G719S, EGFR exon 20 p.S768I, and the emergence of EGFR exon 20 p.C797S.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "EGFR",
              "label": "EGFR exon 18 p.G719S mutation",
              "status": "active"
            },
            {
              "code": "EGFR",
              "label": "EGFR exon 20 p.S768I mutation",
              "status": "active"
            },
            {
              "code": "EGFR",
              "label": "EGFR exon 20 p.C797S",
              "status": "active"
            }
          ],
          "labs": [
            {
              "test": "NGS",
              "value": "EGFR exon 18 p.G719S mutation and EGFR exon 20 p.S768I mutation",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "NGS",
              "value": "retention of EGFR exon 18 p.G719S, EGFR exon 20 p.S768I, and the emergence of EGFR exon 20 p.C797S",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      },
      "custom_id": "graph_076_N1"
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Patient was administered first-line afatinib (40 mg daily po). Patient experienced therapeutic failure, as indicated by time to failure, after 10 and 8 months of afatinib treatment. The patient in this case did not exhibit T790M mutation after progressing on afatinib treatment.",
        "clinical_data": {
          "medications": [
            {
              "drug": "Afatinib",
              "dosage": "40 mg",
              "frequency": "daily",
              "modality": "oral",
              "indication": "therapeutic failure"
            }
          ]
        }
      },
      "custom_id": "graph_076_N2"
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "October 2020, developed new brain lesions after a 10-month period of stability. Lung lesion stable disease (SD) but head lesions partial response (PR) on afitinib treatment.",
        "clinical_data": {
          "imaging": [
            {
              "body_part": "Brain",
              "finding": "new brain lesions",
              "date": "2020-10",
              "modality": "unknown"
            },
            {
              "body_part": "Lung",
              "finding": "stable disease",
              "date": "2020-10",
              "modality": "unknown"
            },
            {
              "body_part": "Head",
              "finding": "partial response",
              "date": "2020-10",
              "modality": "unknown"
            }
          ],
          "medications": [
            {
              "drug": "afitinib",
              "start_date": null,
              "end_date": null
            }
          ]
        }
      },
      "custom_id": "graph_076_N3"
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Patient was then treated with second-line osimertinib (80 mg daily po).",
        "clinical_data": {
          "medications": [
            {
              "drug": "C3888719",
              "dosage": "80 mg",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null
            }
          ]
        }
      },
      "custom_id": "graph_076_N4"
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "February 2021, patient\u2019s brain lesions continued to deteriorate. Third-line afatinib was reverted. Lung lesion stable disease (SD) but head lesions partial response (PR) on osimertinib treatment.",
        "clinical_data": {
          "imaging": [
            {
              "body_part": "Brain",
              "finding": "lesions deteriorated",
              "date": "2021-02",
              "modality": "MRI"
            },
            {
              "body_part": "Lung",
              "finding": "stable disease",
              "date": "2021-02",
              "modality": "CT"
            },
            {
              "body_part": "Head",
              "finding": "partial response",
              "date": "2021-02",
              "modality": "MRI"
            }
          ],
          "medications": [
            {
              "drug": "Afatinib",
              "start_date": "2021-02",
              "end_date": null
            },
            {
              "drug": "Osimertinib",
              "end_date": "2021-02"
            }
          ]
        }
      },
      "custom_id": "graph_076_N5"
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Tumor tissue NGS to determine EGFR mutation status."
      },
      "custom_id": "graph_076_N1_N2"
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Initiation of first-line afatinib treatment based on EGFR mutation profile.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0001527"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_076_N2_N3"
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Progression on afatinib treatment with new brain lesions and stable lung disease.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0239633"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis"
        }
      },
      "custom_id": "graph_076_N3_N4"
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Switch to second-line osimertinib treatment.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C3888719"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_076_N4_N5"
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Brain lesions continue to deteriorate on osimertinib. Reversion to third-line afatinib.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0001527",
            "C3888719"
          ],
          "change_type": "other",
          "target_domain": "medication"
        }
      },
      "custom_id": "graph_076_N5_N6"
    }
  ]
}